Neo-Optalidon (Paracetamol, Propyphenazone, Caffeine)

Paracetamol reduces central prostaglandin production, Propyphenazone inhibits cyclooxygenase enzymes to provide anti‑inflammatory analgesia, and Caffeine blocks adenosine receptors, which enhances the overall pain‑relieving effect and can improve alertness.

The appropriate dose of Neo-Optalidon is determined by the prescribing healthcare professional based on the patient’s age, weight, clinical condition and local regulatory guidelines. Patients should follow the prescriber’s instructions exactly.

Safety in pregnancy and lactation has not been fully established. Healthcare providers should weigh the potential benefits against possible risks and consider alternative therapies when treating pregnant or nursing women.

To place an order, submit an enquiry on the Neo-Optalidon product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Neo-Optalidon combines paracetamol, a non‑opioid analgesic, with propyphenazone and caffeine, offering a broader mechanism of action than single‑ingredient products. This may provide faster or more complete pain relief for certain patients, but the choice of therapy should be individualized by a clinician.

Neo-Optalidon should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children.

Neo-Optalidon is taken orally, usually with a full glass of water. It can be taken with or without food, unless the prescribing information advises otherwise.

Serious risks include severe allergic reactions, liver injury, blood‑related disorders, and rare skin conditions such as Stevens‑Johnson syndrome. Patients should seek immediate medical attention if they experience signs of these reactions.

Individuals with known hypersensitivity to paracetamol, propyphenazone, caffeine or any excipients, as well as patients with severe liver disease, uncontrolled hypertension, or certain cardiac conditions, should avoid Neo-Optalidon unless advised otherwise by a healthcare professional.